Trial · NCT03472469
MAST Trial: Multi-modal Analgesic Strategies in Trauma
NCT03472469, Phase 4, Completed, The University of Texas Health Science Center, Houston; results first posted 2021-06-10
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. MAST Trial: Multi-modal Analgesic Strategies in Trauma. Trials, record NCT03472469. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03472469
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MAST Trial: Multi-modal Analgesic Strategies in Trauma
- NCT number
- NCT03472469
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 1,561 participants, actual
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Conditions
- Nonspecific Pain Post Traumatic Injury
- Interventions
- Acetaminophen IV/PO, Acetaminophen PO, Ketorolac, Celebrex, Naproxen, Tramadol, Pregabalin, Gabapentin, Lidocaine, Opioids, Regional anesthesia
- First posted
- 2018-03-21
- Last updated
- 2021-06-18
- Results first posted
- 2021-06-10
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Opioid Use Per Day | until discharge from hospital or 30 days post admission (whichever is sooner) | Opioid use per day is calculated by tallying the dose equivalency of all opioids received and dividing by the number of days hospitalized. Morphine milligram equivalents (MME) per day are reported. |
| Secondary | Pain as Assessed by Score on the Numeric Rating Scale (NRS) | until discharge from hospital or 30 days post admission (whichever is sooner) | An average will be calculated of the daily numeric rating scale (NRS) for pain (0=no pain, 10=worst pain). This assessment is used in verbal participants. |
| Secondary | Pain as Assessed by Score on the Behavioral Pain Scale (BPS) | until discharge from hospital or 30 days post admission (whichever is sooner) | An average will be calculated of the daily score on the Behavioral Pain Scale (BPS). BPS score ranges from 3-12, with higher scores indicating worse pain. This assessment is used in non-verbal participants. |
| Secondary | Number of Participants Discharged From the Hospital With an Opioid Prescription | Up to 30 days | |
| Secondary | Number of Participants With Any Opioid-related Complications | until discharge from hospital or 30 days post admission (whichever is sooner) | Opioid-related complications include ileus, aspiration, unplanned intubation, unplanned admission to an intensive care unit, and use of an opioid-reversal agent. |
| Secondary | Overall Costs | until discharge from hospital or 30 days post admission (whichever is sooner) | the costs associated with the overall hospitalization or the first 30 days (whichever is sooner) related to post trauma care and complications incurred. |
| Secondary | Pharmacy Costs | until discharge from hospital or 30 days post admission (whichever is sooner) | The costs of the pain medications given during the specified time period. |
| Secondary | Number of Ventilator Days | 30 days | The number of days the patient on a ventilator post injury or up to 30 days (whichever is sooner). Zero-inflated models are presented as estimated marginal means (95% Credible Interval). The data reported as "mean" actually refers to "marginal mean," and the data reported as "95% Confidence Interval" actually refers to a "95% Credible Interval." |
| Secondary | Number of Hospital Days | 30 days | The number of days the patient was hospitalized post injury or up to 30 days (whichever is sooner). Zero-inflated models are presented as estimated marginal means (95% Credible Interval). The data reported as "mean" actually refers to "marginal mean," and the data reported as "95% Confidence Interval" actually refers to a "95% Credible Interval." |
| Secondary | Number of Intensive Care Unti (ICU) Days | 30 days | The number of days the patient was in the ICU post injury or up to 30 days (whichever is sooner). Zero-inflated models are presented as estimated marginal means (95% Credible Interval). The data reported as "mean" actually refers to "marginal mean," and the data reported as "95% Confidence Interval" actually refers to a "95% Credible Interval." |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Opioid Use Per Day | until discharge from hospital or 30 days post admission (whichever is sooner) | MME per day | MEDIAN | |
| SECONDARY | Pain as Assessed by Score on the Numeric Rating Scale (NRS) | until discharge from hospital or 30 days post admission (whichever is sooner) | This data was only collected from 739 in the Original MMPR arm and 735 in the MAST MMPR arm. | units on a scale | MEDIAN |
| SECONDARY | Pain as Assessed by Score on the Behavioral Pain Scale (BPS) | until discharge from hospital or 30 days post admission (whichever is sooner) | This data was only collected from 156 in the Original MMPR arm and 150 in the MAST MMPR arm. | score on a scale | MEDIAN |
| SECONDARY | Number of Participants Discharged From the Hospital With an Opioid Prescription | Up to 30 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Any Opioid-related Complications | until discharge from hospital or 30 days post admission (whichever is sooner) | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Overall Costs | until discharge from hospital or 30 days post admission (whichever is sooner) | dollars | MEDIAN | |
| SECONDARY | Pharmacy Costs | until discharge from hospital or 30 days post admission (whichever is sooner) | dollars | MEDIAN | |
| SECONDARY | Number of Ventilator Days | 30 days | ventilator days | MEAN | |
| SECONDARY | Number of Hospital Days | 30 days | hospital days | MEAN | |
| SECONDARY | Number of Intensive Care Unti (ICU) Days | 30 days | ICU days | MEAN |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 outcomesResults by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Opioid Use Per Day | Original MMPR - Descending Dose Arm | 48 | Inter-Quartile Range 22 to 74 | MME per day | |
| Opioid Use Per Day | MAST MMPR - Escalating Dose Arm | 34 | Inter-Quartile Range 15 to 61 | MME per day | |
| Pain as Assessed by Score on the Numeric Rating Scale (NRS) | Original MMPR - Descending Dose Arm | 3.3 | Inter-Quartile Range 1.8 to 4.8 | units on a scale | |
| Pain as Assessed by Score on the Numeric Rating Scale (NRS) | MAST MMPR - Escalating Dose Arm | 3.3 | Inter-Quartile Range 1.8 to 4.7 | units on a scale | |
| Pain as Assessed by Score on the Behavioral Pain Scale (BPS) | Original MMPR - Descending Dose Arm | 2.5 | Inter-Quartile Range 2.1 to 3.0 | score on a scale | |
| Pain as Assessed by Score on the Behavioral Pain Scale (BPS) | MAST MMPR - Escalating Dose Arm | 2.3 | Inter-Quartile Range 1.8 to 3.0 | score on a scale | |
| Number of Participants Discharged From the Hospital With an Opioid Prescription | Original MMPR - Descending Dose Arm | 527 | Participants | ||
| Number of Participants Discharged From the Hospital With an Opioid Prescription | MAST MMPR - Escalating Dose Arm | 476 | Participants | ||
| Number of Participants With Any Opioid-related Complications | Original MMPR - Descending Dose Arm | Unplanned intubation | 16 | Participants | |
| Number of Participants With Any Opioid-related Complications | MAST MMPR - Escalating Dose Arm | Unplanned intubation | 16 | Participants |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Original MMPR - Descending Dose Arm | 787 | |
| Overall Study | STARTED | MAST MMPR - Escalating Dose Arm | 774 | |
| Overall Study | COMPLETED | Original MMPR - Descending Dose Arm | 787 | |
| Overall Study | COMPLETED | MAST MMPR - Escalating Dose Arm | 774 | |
| Overall Study | NOT COMPLETED | Original MMPR - Descending Dose Arm | 0 | |
| Overall Study | NOT COMPLETED | MAST MMPR - Escalating Dose Arm | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Death | General disorders | Original MMPR - Descending Dose Arm | 29 | 787 | 787 |
| serious | Death | General disorders | MAST MMPR - Escalating Dose Arm | 36 | 774 | 774 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Original MMPR - Descending Dose Arm | 29 | 787 |
| Total, all-cause mortality | MAST MMPR - Escalating Dose Arm | 36 | 774 |
| Total, other adverse events | Original MMPR - Descending Dose Arm | 0 | 787 |
| Total, other adverse events | MAST MMPR - Escalating Dose Arm | 0 | 774 |
| Total, serious adverse events | Original MMPR - Descending Dose Arm | 29 | 787 |
| Total, serious adverse events | MAST MMPR - Escalating Dose Arm | 36 | 774 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants2
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| KL2TR000370 | Center for Clinical and Translational Sciences (CCTS) | MCPHERSON, DAVID D | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2012 to 2016 | NIH RePORTER |
| UL1TR000371 | Center for Clinical and Translational Sciences (CCTS) | MCPHERSON, DAVID D | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2012 to 2016 | NIH RePORTER |
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Original MMPR - Descending Dose Arm vs MAST MMPR - Escalating Dose Arm: Number of Participants Discharged From the Hospital With an Opioid Prescription | Trial comparisons |
| Original MMPR - Descending Dose Arm vs MAST MMPR - Escalating Dose Arm: deaths from any cause | Trial comparisons |
| Original MMPR - Descending Dose Arm vs MAST MMPR - Escalating Dose Arm: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03472469
GET https://conductscience.org/api/trials/v1/NCT03472469/results?page=2